WEX Inc. Announces First Quarter 2025 Financial Results
WEX Inc. (NYSE: WEX), a leading global commerce platform that simplifies the business of running a business, today announced its financial results for the first quarter ended March 31, 2025.…
Category News
Read MoreWEX Inc. Announces First Quarter 2025 Financial Results
BIOQUAL Announces Retirement of President and CEO Dr. Mark G. Lewis
BIOQUAL Announces Retirement of President and CEO Dr. Mark G. Lewis; Dr. Hanne Andersen Elyard Named as Successor BIOQUAL, Inc., a leading provider of in vivo and in vitro preclinical…
AtriCure Announces First Quarter 2025 Financial Results
AtriCure Reports Strong First Quarter 2025 Financial Results Driven by Product Innovation and Market Expansion AtriCure, Inc. (Nasdaq: ATRC), a global leader in developing innovative surgical solutions for the treatment…
Sage Therapeutics Delivers Q1 2025 Results, Showcases Pipeline Progress and Strategic Developments
Sage Therapeutics Reports First Quarter 2025 Financial Results, Showcases Strong Momentum for ZURZUVAE and Pipeline Advancements Sage Therapeutics, Inc. (Nasdaq: SAGE) has announced its financial results for the first quarter…
Mirion Reports Q1 2025 Financial Results and Revises Full-Year Outlook
Mirion Reports Strong First Quarter 2025 Results and Updates Full-Year Guidance Amid Robust Market Demand Mirion Technologies, Inc. (“Mirion” or the “Company”) (NYSE: MIR), a leading provider of radiation detection,…
Devonian Health Group Announces Resumption of Trading on TSXV
Devonian Health Group Inc. Announces Reinstatement of Trading on TSX Venture Exchange Following Resolution of Cease Trade Order Devonian Health Group Inc. (“Devonian” or the “Company”) (TSXV: GSD; OTCQB: DVHGF),…
Puma Biotechnology Showcases Neratinib Clinical Findings at AACR Annual Meeting 2025
Puma Biotechnology Showcases Promising Neratinib Combination Data at AACR Annual Meeting 2025 Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company specializing in the development of innovative cancer treatments, has presented…
Contineum Therapeutics Names Dr. Timothy Watkins as Chief Medical Officer and Head of Development
Contineum Therapeutics Names Dr. Timothy Watkins as Chief Medical Officer and Head of Development, Signaling Strategic Growth in Clinical Pipeline Contineum Therapeutics, Inc. (Nasdaq: CTNM), a clinical-stage biopharmaceutical company advancing…
Medifast Releases First Quarter 2025 Earnings
Medifast Reports First Quarter 2025 Financial Results, Focuses on Revitalizing Growth and Enhancing Wellness Offerings Medifast, a leading health and wellness company known for its clinically supported and coach-guided lifestyle…
Merck KGaA, Darmstadt, Germany, to Acquire SpringWorks Therapeutics to Drive Sustainable Growth in Healthcare Portfolio
Merck KGaA, Darmstadt, Germany, to Acquire SpringWorks Therapeutics in Strategic Move to Accelerate Healthcare Growth Merck KGaA, Darmstadt, Germany (DAX: MRK), a global leader in science and technology, today announced…
CareDx to Present 60 Abstracts, 19 Oral, at 2025 ISHLT Meeting
CareDx to Present 60 Abstracts, 19 Oral, at 2025 ISHLT Meeting CareDx, Inc. (Nasdaq: CDNA), known as The Transplant Company™, has announced it will present 60 abstracts—including 19 oral presentations—at…
Novocure’s Optune Lua® Gets CE Mark for mNSCLC Treatment
Novocure’s Optune Lua® Gets CE Mark for mNSCLC Treatment Novocure (NASDAQ: NVCR) has announced that its Optune Lua® device has received the CE Mark (Conformité Européenne) for treating adult patients…